Skip to main content

Advertisement

SpringerLink
Log in

The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma

  • Melanoma
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose and Methods

Completion lymph node dissection (CLND) for sentinel lymph node (SLN)-positive melanoma patients has been guideline-concordant standard of care since adoption of lymphatic mapping and SLN biopsy for the management of clinically node-negative melanoma patients more than 20 years ago. However, a trend for omission of CLND has been observed over the past decade, and we now have randomized, controlled clinical trial data to help guide treatment recommendations. Publication of these data prompted an American Society of Clinical Oncology—Society of Surgical Oncology 2018 clinical practice guideline update for these patients.

Results and Conclusions

Systematic review of current evidence supports a selective, individualized approach to CLND for SLN-positive melanoma. For low-risk, low-volume micrometastatic disease, SLN biopsy may be both diagnostic and therapeutic, and close clinical follow-up with imaging or CLND are reasonable options for appropriately selected patients. For higher-risk patients, omission of CLND requires careful consideration of risks versus benefits, relevant histopathology, and individualized patient discussion. This should address patient comorbidities and life expectancy, the predicted likelihood of additional positive nodes, availability of imaging surveillance, likelihood of adherence to imaging and clinical follow-up, consequences of regional recurrence, and the prognostic value of complete nodal staging and its impact on adjuvant therapy recommendations or clinical trial participation. Data on long-term outcomes, cost, and patient-reported quality of life measures are not yet available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–9.

    Article  PubMed  CAS  Google Scholar 

  2. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline–Update 2012. Eur J Cancer. 2012;48(15):2375–90.

    Article  PubMed  Google Scholar 

  3. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. NCCN Clinical Practice Guidelines in Oncology: Melanoma, v1.2017. 2017. www.nccn.org. Accessed 1 Feb 2017.

  5. Lee DY, Lau BJ, Huynh KT, et al. Impact of completion lymph node dissection on patients with positive sentinel lymph node biopsy in melanoma. J Am Coll Surg. 2016;223(1):9–18.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Erickson Foster J, Velasco JM, Hieken TJ. Adverse outcomes associated with noncompliance with melanoma treatment guidelines. Ann Surg Oncol. 2008;15(9):2395–402.

    Article  PubMed  Google Scholar 

  7. Schuitevoerder D, Bubic I, Fortino J, Massimino KP, Vetto JT. Patients with sentinel lymph node positive melanoma: who needs completion lymph node dissection? Am J Surg. 2018;215(5):868–72.

    Article  PubMed  Google Scholar 

  8. Cormier JN, Xing Y, Ding M, et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005;23(25):6054–62.

    Article  PubMed  Google Scholar 

  9. Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15(6):1566–76.

    Article  PubMed  Google Scholar 

  10. Chu BS, Koffi W, Hoehn RS, et al. Improvement and persistent disparities in completion lymph node dissection: lessons from the National Cancer Database. J Surg Oncol. 2017;116(8):1176–84.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008;26(26):4296–303.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Pasquali S, Mocellin S, Mozzillo N, et al. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. J Clin Oncol. 2014;32(9):935–41.

    Article  PubMed  Google Scholar 

  13. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67.

    Article  PubMed  Google Scholar 

  14. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol 2018;25(2):356–77.

    Article  PubMed  Google Scholar 

  16. American College of Surgeons Clinical Research Program, MHG Katz (eds). Operative standards for cancer surgery. Volume II: esophagus, melanoma, rectum, stomach, thyroid. Wolters Kluwer; 2018.

  17. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351(9105):793–6.

    PubMed  CAS  Google Scholar 

  18. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–17.

    Article  PubMed  CAS  Google Scholar 

  19. Callender GG, McMasters KM. Early versus delayed complete lymphadenectomy in melanoma: insight from MSLT I. Ann Surg Oncol. 2011;18(2):306–8.

    Article  PubMed  Google Scholar 

  20. Pasquali S, Sommariva A, Spillane AJ, Bilimoria KY, Rossi CR. Measuring the quality of melanoma surgery—highlighting issues with standardization and quality assurance of care in surgical oncology. Eur J Surg Oncol. 2017;43(3):561–71.

    Article  PubMed  CAS  Google Scholar 

  21. Minami CA, Wayne JD, Yang AD, et al. National evaluation of hospital performance on the new commission on cancer melanoma quality measures. Ann Surg Oncol. 2016;23(11):3548–57.

    Article  PubMed  Google Scholar 

  22. Grotz TE, Huebner M, Pockaj BA, Perkins S, Jakub JW. Limitations of lymph node ratio, evidence-based benchmarks, and the importance of a thorough lymph node dissection in melanoma. Ann Surg Oncol. 2013;20(13):4370–7.

    Article  PubMed  Google Scholar 

  23. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–34.

    Article  PubMed  CAS  Google Scholar 

  24. Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 2009;36(10):1713–42.

    Article  PubMed  CAS  Google Scholar 

  25. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29(11):1479–87.

    Article  PubMed  Google Scholar 

  27. Ghaferi AA, Wong SL, Johnson TM, et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol. 2009;16(11):2978–84.

    Article  PubMed  Google Scholar 

  28. Ariyan C, Brady MS, Gonen M, Busam K, Coit D. Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16(1):186–90.

    Article  PubMed  Google Scholar 

  29. Brown RE, Ross MI, Edwards MJ, et al. The prognostic significance of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2010;17(12):3330–5.

    Article  PubMed  Google Scholar 

  30. Leung AM, Morton DL, Ozao-Choy J, et al. Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg. 2013;148(9):879–84.

    Article  PubMed  Google Scholar 

  31. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201(1):37–47.

    Article  PubMed  Google Scholar 

  32. Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22(18):3677–84.

    Article  PubMed  Google Scholar 

  33. Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28(29):4441–9.

    Article  PubMed  Google Scholar 

  34. Wevers KP, Murali R, Bastiaannet E, et al. Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. Eur J Surg Oncol. 2013;39(2):179–84.

    Article  PubMed  CAS  Google Scholar 

  35. Feldmann R, Fink AM, Jurecka W, Rappersberger K, Steiner A. Accuracy of the non-sentinel node risk score (N-SNORE) in patients with cutaneous melanoma and positive sentinel lymph nodes: a retrospective study. Eur J Surg Oncol 2014;40(1):73–6.

    Article  PubMed  CAS  Google Scholar 

  36. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 2003;10(6):676–80.

    Article  PubMed  Google Scholar 

  37. Theodore JE, Frankel AJ, Thomas JM, et al. Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma. ANZ J Surg 2017;87(1–2):44–8.

    Article  PubMed  Google Scholar 

  38. Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 2015;16(9):1049–60.

    Article  PubMed  Google Scholar 

  39. Sabel MS, Griffith KA, Arora A, et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery. 2007;141(6):728–35.

    Article  PubMed  Google Scholar 

  40. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010;17(12):3324–9.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Egger ME, Kimbrough CW, Stromberg AJ, et al. Melanoma patient-reported quality of life outcomes following sentinel lymph node biopsy, completion lymphadenectomy, and adjuvant interferon: results from the Sunbelt Melanoma Trial. Ann Surg Oncol. 2016;23(3):1019–25.

    Article  PubMed  Google Scholar 

  42. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in Stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23.

    Article  PubMed  CAS  Google Scholar 

  44. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.

    Article  PubMed  CAS  Google Scholar 

  45. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801.

    Article  PubMed  CAS  Google Scholar 

  46. Meves A, Nikolova E, Heim JB, et al. Tumor cell adhesion as a risk factor for sentinel lymph node metastasis in primary cutaneous melanoma. J Clin Oncol. 2015;33(23):2509–15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Maus RLG, Jakub JW, Nevala WK, et al. Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front Immunol. 2017;8:358.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Egger ME, Xiao D, Hao H, et al. Unique genes in tumor-positive sentinel lymph nodes associated with nonsentinel lymph node metastases in melanoma. Ann Surg Oncol. 2018;25(5):1296–303.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Mayo Clinic, Rochester, MN, USA

    Tina J. Hieken MD

  2. Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    John M. Kane III MD

  3. Department of Surgery, Geisel School of Medicine at Dartmouth, Hanover, NH, USA

    Sandra L. Wong MD

Authors
  1. Tina J. Hieken MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. Kane III MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandra L. Wong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina J. Hieken MD.

Ethics declarations

Disclosure

The authors have no relevant conflicts of interest to report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hieken, T.J., Kane, J.M. & Wong, S.L. The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma. Ann Surg Oncol 26, 1028–1034 (2019). https://doi.org/10.1245/s10434-018-6812-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6812-z

Search

Navigation